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Treatment of Fragile X Syndrome with Cannabidiol:
A Case Series Study and Brief Review of the Literature
Nicole Tartaglia,1 Marcel Bonn-Miller,2 and Randi Hagerman3,*
Abstract
Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation
1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anx-
iety, poor sleep, and cognitive deficits, as well as populations with endocannabinoid deficiencies, such as those
who suffer from FXS. The objective of this study was to provide a brief narrative review of recent literature on endo-
cannabinoids and FXS and to present a case series describing three patients with FXS who were treated with oral
CBD-enriched (CBD+) solutions. We review recent animal and human studies of endocannabinoids in FXS and pres-
ent the cases of one child and two adults with FXS who were treated with various oral botanical CBD+ solutions
delivering doses of 32.0 to 63.9mg daily. Multiple experimental and clinical models of FXS combine to highlight the
therapeutic potential of CBD for management of FXS. All three patients described in the case series exhibited func-
tional benefit following the use of oral CBD+ solutions, including noticeable reductions in social avoidance and
anxiety, as well as improvements in sleep, feeding, motor coordination, language skills, anxiety, and sensory pro-
cessing. Two of the described patients exhibited a reemergence of a number of FXS symptoms following cessation
of CBD+ treatment (e.g., anxiety), which then improved again after reintroduction of CBD+ treatment. Findings
highlight the importance of exploring the therapeutic potential of CBD within the context of rigorous clinical trials.
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Introduction
Fragile X syndrome (FXS) is an X-linked dominant dis-
order caused by the expansion of a trinucleotide repeat
(CGG)n within the first exon of the fragile X mental re-
tardation 1 (FMR1) gene, which silences the expression
of the fragile X mental retardation protein (FMRP).1
The absence of FMRP, an important regulator of trans-
lation of many messenger RNAs involved in synaptic
plasticity,2 leads to substantial intellectual deficits.
The condition has been estimated to affect *1:4000
males and 1:7000 females.3–5 Although both sexes are
susceptible, males with FXS typically exhibit more se-
vere symptoms compared with females because the sin-
gle X chromosome in males is usually fully methylated
and not producing FMRP6; females typically have some
FMRP expression from the FMR1 gene on their second
unaffected X chromosome.7 Males with FXS are far
more likely than females to exhibit significant intellec-
tual and developmental disabilities (85% vs. 25%).8
Among individuals with the full mutation (i.e., >200
CGG repeats), symptoms of FXS vary by age and sex,
but often include anxiety (80%), social avoidance
(80%), stereotyped behaviors (80%), attention-deficit/
hyperactivity disorder (70%), autism spectrum disor-
ders (60%), intellectual disability (85% of males and
25% of females), aggression (40%), disrupted sleep pat-
terns (40%), and epilepsy (16%), as well as macroorch-
idism (90% of adults), prominent ears (60%), long faces
(60%), soft skin (50%), and hyperextensible joints (60%
of children).9–11 Traditional allopathic treatment of
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these patients may involve medications to address issues
with sleep (melatonin and clonidine), anxiety (selective
serotonin reuptake inhibitors and benzodiazepines),
hyperactivity and deficits in attention (psychostimu-
lants), and seizures (carbamazepine, valproic acid, and
lamotrigine).12 Yet, for many patients with FXS, the
aforementioned pharmacotherapies, when used alone
or in combination, have suboptimal efficacy and toler-
ability,11–13 suggesting a persistent unmet medical need
for novel, interventional treatment approaches for pa-
tients with FXS. Because the clinical abnormalities in
these patients (and most recently in children with au-
tism spectrum disorder14) have been linked, at least
in part, with dysregulation of the endocannabinoid sys-
tem, we briefly review recent research characterizing
the involvement of the endocannabinoid system in
FXS and present the cases of three individuals (one
child and two adults) with FXS who experienced func-
tional benefit after treatment with cannabidiol (CBD)-
enriched (CBD+) preparations.
Endocannabinoids and FXS
The endocannabinoid system consists of receptors in
the brain and peripheral tissues that are involved
in numerous physiological processes as well as the endo-
cannabinoids, N-arachidonoylethanolamine (ananda-
mide; AEA) and 2-arachidonoylglycerol (2-AG). The
endocannabinoids bind to the G-protein-coupled recep-
tors, cannabinoid 1 and 2 (CB1 and CB2),
15,16 and mod-
ulate synaptic transmission throughout the central
nervous system.17,18 Receptors are distributed through-
out the body, with CB1 receptors abundantly expressed
in the brain and present at lower concentrations in a
variety of peripheral tissues and cells and CB2 receptors
expressed primarily in the immune and hematopoietic
systems, as well as in the brain, pancreas, and bone.16
CBD, the primary, noneuphoric exogenous phyto-
cannabinoid in cannabis, may attenuate the loss of
endogenous cannabinoid (i.e., endocannabinoid) sig-
naling observed in preclinical models of FXS, allowing
a component of the FMRP deficiency inherent in FXS
to be bypassed. Specifically, many abnormalities seen
in FXS appear to be rooted in dysregulation of the
endocannabinoid pathways in the central nervous sys-
tem, with a reduction of endogenous stimulation of
endocannabinoid receptors.19–21 CBD has the capacity
to interact with an FXS-compromised endocannabinoid
system. Indeed, deletion of FMRPwithin a mouse model
of FXS led to reduced production of 2-AG, decreasing
activation of CB1 receptors in the central nervous sys-
tem.20 CBD has been shown to increase 2-AG availabil-
ity,22 potentially attenuating or reversing one of the
biological mechanisms of abnormal cellular function
in FXS.20 Importantly, CB1 protein expression appears
unaffected in FMR1 knockout (KO) mice, suggesting
that the downstream elements of endocannabinoid sig-
naling can be engaged, even in the absence of FMRP.19
In addition to the role of 2-AG, recent work has
begun to highlight the potential importance of AEA
in addressing social impairment as well as deficits in
learning and memory among those with FXS. In an
FMR1 KO mouse model of FXS, Qin et al. demon-
strated that increased levels of AEA were associated
with greater cognitive performance.23 Similarly, Wei
et al. utilized mouse models of FXS to show that
AEA-mediated signaling at CB1 receptors, driven by
oxytocin, controls social reward24 and that increasing
AEA activity resulted in reductions in social impair-
ment.25 Much like its impact on 2-AG, CBD has been
shown to increase levels of AEA by binding to fatty
acid-binding proteins, which transport AEA to the cat-
abolic enzyme fatty acid amide hydrolase, an enzyme
that breaks down AEA.26–28 Binding to fatty acid-
binding proteins is thought to increase AEA availability
and CB1 activation.
CBD and FXS: Other Mechanisms of Action
The mechanisms underlying the potential benefits of
CBD for FXS span far beyond the endocannabinoid
system. Beyond providing benefit to patients with
FXS through increases in 2-AG and AEA availability,
CBD may positively affect synaptic plasticity. Studies
of FMR1 KO mice have identified discrete alterations
in synaptic plasticity in specific brain regions, including
an increase in long-term depression (LTD) in the hip-
pocampus,23,29 and preclinical data suggest that reduc-
ing LTD in FMR1 KO mice requires activation of
endocannabinoid receptors.19 Therefore, it is hypothe-
sized that CBD may increase synaptic plasticity in
FXS, facilitating one of the basic cellular mechanisms
thought to be associated with learning and improve-
ments in cognition.29
More recent work has also begun to identify deficits
in GABA receptor expression among those with FXS.
As FMRP has been shown in animal models to enhance
expression of GABA receptors, the lack of FMRP
among those with FXS has been associated with fewer
GABA receptors.30 Indeed, preclinical studies in
FMR1 KO mice have consistently shown downregula-
tion of the GABA system.11 As CBD acts as a positive
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allosteric modulator of GABA-A receptors,31 CBDmay
also act to enhance the binding affinity for GABA.
The impact of CBD on serotonin represents a mech-
anism by which CBD may aid in reduction of social
anxiety and resulting avoidance experienced by pa-
tients with FXS. Indeed, the anxiolytic effects of CBD
have been reported in over 30 preclinical studies,
using multiple models of anxiety (i.e., generalized anx-
iety, stress-induced anxiety, panic disorder, and con-
textual fear conditioning),32,33 as well as in a growing
number of human studies, including within-social anx-
iety.32,34 Several preclinical studies have identified the
serotonin 1A receptor as one mechanism through
which CBD exerts its anxiolytic effects.35,36
Case Reports
We report the cases of three patients with diagnosed
FXS who received oral forms of botanically derived
CBD+ solutions and reported clinical symptom im-
provement.
Patient 1
Patient 1 is a 3-year 6-month-old male with FXS diag-
nosed at age 15 months with 250 to 650 CGG repeats.
He was born full-term following an uncomplicated
pregnancy and delivery at seven pounds six ounces.
In the newborn period, he began having problems
latching for breastfeeding, and he was fed pumped
breast milk and formula from a bottle; he had frequent
gagging and spitting up. By 6 months of age, with intro-
duction of soft baby foods, he was often dysphagic,
choked easily, and was intolerant of chunky or textured
foods. Testing for food allergies was negative, and his
formula was changed multiple times over his first
year of life. He grew slowly at the third to fifth percen-
tile for weight and the 50th percentile for length until
15 months of age. He was also hypotonic with delays
in gross motor skills. He had behavioral concerns, in-
cluding atypical motor movements, frequent repetitive
moving, stiffening and shaking of his legs, body rock-
ing, and repetitive finger stereotypies while touching
his ears. He displayed difficulty adjusting to new or
noisy places and changes in routine, as well as trouble
making eye contact and a short attention span during
play and in social interactions; he would sometimes
stare off and seem disconnected for 10 to 30 sec.
At 15 months of age, he was evaluated and under-
went a brain magnetic resonance imaging (MRI), elec-
troencephalography (EEG), creatine kinase, plasma
amino acids, and thyroid and genetic testing. His
MRI, EEG, microarray, and laboratory parameters
were normal. His FXS DNA test results showed a full
mutation for FXS with 260 to 650 fully methylated
CGG repeats.
At this time, the patient’s parents independently
obtained and began administering an oral paste com-
prising 18% to 23.5% CBD and trace amounts
(0.03%) of delta-9-tetrahydrocannabinol (THC) that
delivered 50mg of CBD per day (RSHO Blue Label;
Naturewell, Inc., San Diego, CA). They combined the
CBD paste with coconut oil, heated the mixture until
it liquefied, and then used a syringe to administer the
liquid preparation orally. During the first month of
CBD+ treatment, the family noticed behavioral im-
provements.
After 1 month of CBD+ monotherapy, the then 16-
month-old patient began specialized care in the form of
speech and language therapy and occupational therapy
for FXS. A baseline measure of adaptive functioning
was obtained (Table 1). Over the next 3 months of
daily 50-mg CBD+ treatment with adjunctive therapy,
the family noted continued improvements in a wide
range of clinical parameters. Feeding improved mark-
edly with increased willingness to eat solid foods and
increased intake overall. His parents also noted im-
provements in motor coordination, more frequent vo-
calizations, less rocking and kicking during feeds, more
frequent and longer eye contact, an increase in positive
interactions with other children, greater willingness to
explore new places, and less self-stimulatory behavior.
Many of the parental observations were also confirmed
by the patient’s occupational and speech therapists,
some of whom were unaware of the initiation of
CBD+ treatment. CBD+ solution was the only medica-
tion used in treatment during this time.
Table 1. Patient 1: Adaptive Functioninga at 1 Year
4 Months of Age and 3 Years 0 Months of Age
1 year 4 months 3 years 0 months
Standardized
scoreb
Percentile Standardized
scoreb
Percentile
Communication 84 14th 87 19th
Daily living skills 71 3rd 77 6th
Socialization 86 18th 79 8th
Motor skills 78 7th 70 2nd
Adaptive behavior
composite
76 5th 75 5th
aVineland adaptive behavior scales, second edition—parent survey.
bMean– SD= 100– 15.
SD, standard deviation.
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At the 4-month follow-up visit, the patient’s weight
had increased to the 15th percentile, while his length
remained at the 50th percentile. Developmental prog-
ress included improved fine and gross motor skills, de-
creased repetitive rocking, improved social interest/
engagement, improved vocalizations, and decreased
hyperactivity. The patient began a regimen of sertraline
(2.5mg per day) due to preliminary evidence of im-
proved language and development in young children
with FXS treated with sertraline.37,38 Subsequent
follow-up visits (at 21 and 27 months of age) showed
continued improvement in language and developmen-
tal skills. The patient started walking and self-feeding
independently, exhibited more frequent and varied vo-
calizations, fewer repetitive and motor behaviors, fewer
sensory sensitivities (e.g., tolerated noise and lights of
fireworks), and more frequent initiation of joint atten-
tion with pointing. Weight increased to the 25th percen-
tile. He continued using CBD+ solution and remained
in a strong early intervention program: 1 h per week of
occupational, speech, and physical therapy; 6 h per
week of Early Start Denver Model behavioral therapy
and applied behavioral analysis.
When the patient was 30 months of age, his parents
chose to discontinue CBD+ treatment to instead ex-
plore minocycline, shown to improve behavioral symp-
toms in some patients with FXS.39 The initiation of
25mg per day of minocycline coupled with cessation
of CBD+ treatment resulted in increased anxiety,
more frequent meltdowns, and more difficulty falling
and maintaining sleep.
During a clinic visit when the patient was 3 years of
age, it was noted that the patient continued to engage
and make slow progress, although anxiety, frequent
meltdowns, and difficulties with sleep persisted, and
increasing challenges with transitions and attention
span were observed. The patient’s medical treatments
included a daily regimen of 4mg of sertraline and
25mg of minocycline. He also continued to receive in-
tensive early intervention services (as described above).
At 3 years of age, an updated adaptive behavior assess-
ment was obtained (Table 1). After discussion with his
family and medical team, the patient was restarted on
CBD+ treatment, 50mg per day. Following reinitia-
tion of CBD+ treatment, his parents noted reductions
in anxiety, fewer meltdowns, and improvements in
his ability to fall and stay asleep. The patient has
now transitioned into a small preschool where he is
continuing to do well and has remained on his CBD+
treatment.
Patient 2
Patient 2 is a 26-year-old male with full-mutation (>200
CGG repeats) FXS and an IQ score in the mid-50s.
Despite a medication regimen that included 60mg of
methylphenidate hydrochloride (once daily), 2.5mg of
aripiprazole, 100mg of sertraline, 200mg of minocy-
cline, and 0.2mg of clonidine (at bedtime), the patient
experienced significant symptoms of attention-deficit/
hyperactivity disorder, including hyperactivity, inatten-
tion, and impulsivity. He also suffered from anxiety,
which led to avoidant behavior and sleep disturbances,
and some significant features of autism, including social
avoidance, poor eye contact, perseverative behavior,
hand stereotypies, and tactile defensiveness.
Due to ongoing symptomatology, the patient began
taking a liquid preparation containing 63.9% CBD,
4% cannabichromene, 3.4% THC, and 0.7% phenylbi-
guanide, delivered orally by a 1-mL syringe. The pa-
tient’s parents obtained the solution independent of
their physician. Between 0.05 and 0.1mL (i.e., 32.0–
63.9mg CBD) of the oral solution was delivered in
the morning, once per day for 6 weeks, during which
time other therapies remained unchanged.
During the first week of treatment with the CBD+
solution, the patient’s family noticed that his anxiety
level was reduced and he was able to explore and par-
ticipate in more activities with less social avoidance.
His facility with language increased, as shown by
greater capacity to engage in longer more meaningful
conversations. The quality and duration of his sleep
also improved; he no longer awoke and wandered in
the middle of the night. His symptoms of anxiety and
linguistic skills continued to improve over the 6-week
course of treatment with the CBD+ solution. His par-
ents have continued him on a stable dose of 0.1mL
daily now for 2 years and have observed sustained
symptom improvement.
Patient 3
Patient 3 is a 22-year-old female who was diagnosed
with FXS at 9 years of age with a full mutation of
>200 CGG repeats. She met all of her early milestones
appropriately, but at around 3 to 4 years of age, she de-
veloped quite significant anxiety and panic attacks.
There was mild benefit associated with initiation of
psychological therapies, although her mother described
difficulties with new settings, social anxiety, frequent
negative perseverative thoughts, and ongoing panic at-
tacks that would vary in frequency depending on her
routine and social supports.
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Starting in the fourth grade, she had mild academic
challenges that were supported with a 504 educational
plan through the end of high school. Ongoing anxiety
was present and trials of St. John’s Wort and other sup-
plements were minimally helpful. She did not receive
any other medication treatment. She graduated from
college with academic supports, with continued periods
of significant anxiety symptoms, social withdrawal, and
panic attacks. After college, she began work as an edu-
cational aide in a public school, with an exacerbation of
anxiety due to this transition into adulthood and pres-
sures of increased independence.
At 22 years of age, her parents provided her with a
liquid formulation of hemp oil containing *43mg of
CBD daily (Charlotte’s Web Everyday Advanced;
CWB Holdings, Inc., Denver, CO), which she began
taking. She described feeling calmer, with fewer persev-
erative worries, and a cessation of panic attacks. This
led to more interactions and activities with peers and
improved performance at work. Her mother also
noted that she became more engaged socially, calmed
more easily when frustrated, and was less likely to fixate
on negative aspects of various situations. She missed
about 1 week of dosing when on a family vacation
out of town, and after a few days without treatment,
she experienced recurrence of anxiety symptoms and
reemergence of panic attacks. These resolved after she
was home and able to restart her CBD+ treatment.
She is currently working full time and living indepen-
dently. She has continued CBD+ treatment for two
and a half years with sustained therapeutic benefit.
Discussion
Based on its morbidity and prevalence, its association
with a number of co-occurring problems, such as sei-
zures, anxiety, and sleep disturbances,13 and the pau-
city of efficacious therapeutic options, FXS represents
an important public health problem.6 The present arti-
cle provides a brief review of recent research that doc-
uments the promise of CBD as a therapeutic agent for
patients with FXS. Also described are the cases of one
pediatric and two adult patients with FXS for whom
CBD+ treatment appears to have contributed to posi-
tive changes in anxiety and/or language skills, with
no observed adverse events.
Before starting CBD+ treatment, Patient 1 experi-
enced heightened symptoms of anxiety, frequent tan-
trums, and sleep difficulties. Over the first month of
CBD+ monotherapy, and subsequent 3 months of
CBD+ treatment combined with speech, language,
and occupational therapy, the patient made consider-
able progress with feeding and weight gain, exhibited
better oral–motor coordination, had decreased social
avoidance and sensory sensitivities, and showed im-
provements in attention span/engagement, the fre-
quency and severity of atypical motor movements,
and general level of hyperactivity. Upon discontinua-
tion of CBD+ treatment, the patient’s prior symptoms
reemerged. While a strong therapy program and later
addition of other medications likely contributed to
this patient’s overall developmental progress, the tem-
porally related improvements in anxiety, feeding, tan-
trums, and sleep—evident when CBD+ treatment was
initially started as monotherapy and then reinstated
following cessation—are compelling support for the
benefits of CBD+ treatment for this patient. By main-
taining his adaptive functioning scores from 1 to 3
years of age, the patient demonstrated a significant im-
provement over the characteristic developmental tra-
jectory of young male children with FXS, where a
decrease in adaptive functioning scores is typically ob-
served between 2 and 6 years of age.40
Patient 2 showed a similarly encouraging response to
CBD+ treatment, experiencing reduced anxiety, im-
proved use of language, and better sleep within 1
week of beginning treatment with a CBD+ solution.
It is also remarkable that the patient continued to dem-
onstrate symptom improvement over the initial 6-week
treatment period, with longer-term follow-up high-
lighting continued use of CBD+ solution with sus-
tained benefit.
In Patient 3, the use of CBD+ solution was also as-
sociated with a positive effect in a higher functioning
female with FXS and long-standing anxiety symptoms.
Similar to Patient 1, treatment discontinuation was as-
sociated with a recurrence of anxiety symptoms, with
reinitiation of CBD+ treatment leading to symptom
improvement and resulting long-term use.
The present findings, coupled with the available pre-
clinical data, highlight the potential for CBD as an in-
tervention for individuals with FXS. The existing
literature combines to demonstrate that CBD may pos-
itively impact individuals with FXS through many
mechanisms, including the endocannabinoid system,
GABA, and serotonin. While a number of drugs have
been developed to target specific systems (e.g., GABA
agonists), CBD has the potential to yield a multifaceted
benefit to individuals with FXS due to its multiple
mechanisms of action. CBD has not only been shown
to be generally well tolerated relative to other treatments
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used in this population,41 but also numerous studies
have documented its benefits in terms of sleep quali-
ty,42,43 anxiety (including social anxiety),34,44 and cog-
nitive impairment45—symptoms experienced by the
individuals profiled in the present case series.
These data serve as stepping stones upon which
proof-of-concept open-label trials should be based.
As with many patients, however, those discussed herein
used orally administered botanical CBD+ solution that
is not regulated by the Food and Drug Administration
and, thus, inconsistencies in availability, quality, purity,
and labeling46,47 make research, interpretations, and
clinical recommendations challenging. The present
case series is limited by its reliance on manufacturer-
reported cannabinoid content as well as the lack of
multimethod assessment of patient symptomatology,
including clinimetric data. The observed clinical benefit
of CBD+ treatment in case studies, particularly with re-
spect to caregiver-reported behavioral outcomes, must
also be interpreted with caution given the significant
placebo effects that have been documented in clinical
trials of CBD.48 Only placebo-controlled trials will be
able to elucidate the true therapeutic effects of CBD/
CBD+ treatment on FXS symptomatology. Until rigor-
ous clinical trials have demonstrated the efficacy of
CBD/CBD+ treatment for FXS, current treatments
for the many behavioral problems associated with
FXS should be utilized before off-label use of CBD+
products.
In an effort to overcome existing limitations, future
studies should independently test patient samples to
confirm actual constituents of each CBD+ prepara-
tion47 and utilize well-validated caregiver-reported as-
sessments of anxiety and other FXS symptomatology,
in addition to unstructured caregiver- and clinician-
based reports, in an attempt to more completely track
each patient’s course while in clinical care. Due to
inconsistencies observed in many oral botanical prepa-
rations, rigorous examinations of pharmaceutical-grade
preparations of CBD should be explored as potential
treatments for children and adolescents with FXS.
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Abbreviations Used
AEA¼N-arachidonoylethanolamine (anandamide)
2-AG¼ 2-arachidonoylglycerol
CBD¼ cannabidiol
CBD + ¼CBD-enriched
EEG¼ electroencephalography
FMR1¼ fragile X mental retardation 1
FMRP¼ fragile X mental retardation protein
FXS¼ fragile X syndrome
KO¼ knockout
LTD¼ long-term depression
MRI¼magnetic resonance imaging
SD¼ standard deviation
THC¼ tetrahydrocannabinol
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